Ascletis Pharma Inc.
ASCLF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $1,749 | $1,282 | $4,124 | $35 |
| - Cash | $866 | $330 | $2,471 | $2,495 |
| + Debt | $8 | $8 | $4 | $3 |
| Enterprise Value | $891 | $961 | $1,657 | -$2,458 |
| Revenue | $1 | $57 | $54 | $77 |
| % Growth | -97.7% | 4.6% | -29.6% | – |
| Gross Profit | $1 | $26 | -$25 | $39 |
| % Margin | 57.3% | 45.9% | -45.6% | 51% |
| EBITDA | -$390 | -$126 | -$284 | -$169 |
| % Margin | -30,432.6% | -222.8% | -526% | -220.3% |
| Net Income | -$301 | -$145 | -$315 | -$199 |
| % Margin | -23,455.7% | -255.7% | -582.1% | -258.9% |
| EPS Diluted | -0.3 | -0.13 | -0.29 | -0.18 |
| % Growth | -130.8% | 55.2% | -61.1% | – |
| Operating Cash Flow | -$342 | -$144 | -$142 | -$147 |
| Capital Expenditures | -$2 | -$19 | -$14 | -$7 |
| Free Cash Flow | -$344 | -$163 | -$157 | -$154 |